Association of prehospital antiplatelet therapy with survival in patients hospitalized with COVID-19: A propensity score-matched analysis.
Jonathan H ChowYing YinDavid P YamaneDanielle DavisonRyan J KeneallyKatrina HawkinsK Gage ParrMustafa Al-MashatJeffery S BergerReamer L BushardtMichael A MazzeffiStuart J NelsonPublished in: Journal of thrombosis and haemostasis : JTH (2021)
In the largest observational study to date of prehospital antiplatelet therapy in patients with COVID-19, there was an association with significantly lower in-hospital mortality. Randomized controlled trials in diverse patient populations with high rates of baseline comorbidities are needed to determine the ultimate utility of antiplatelet therapy in COVID-19.
Keyphrases
- antiplatelet therapy
- acute coronary syndrome
- percutaneous coronary intervention
- coronavirus disease
- sars cov
- end stage renal disease
- cardiac arrest
- randomized controlled trial
- ejection fraction
- newly diagnosed
- chronic kidney disease
- coronary artery disease
- peritoneal dialysis
- case report
- prognostic factors
- trauma patients
- systematic review
- emergency medical
- clinical trial
- patient reported outcomes
- study protocol
- patient reported